Accelerated approvals

Cancer therapies that have received accelerated approval in the U.S.

Product Approval date Company Indication Basis for accelerated approval U.S. status (for cancer indication)
Gleevec 05/10/01 Novartis (NVS) Chronic myeloid leukemia Overall hematologic and cytogenetic response rates Marketed under accelerated approval
Campath 05/07/01 Millennium (MLNM)/Ilex (ILXO) B cell chronic lymphocytic leukemia refractory to alkylating agents and fludarabine Overall response rate Marketed under accelerated approval